PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Cannabis (medicinal) - Spasticity and muscle spasm

PAD Profile : Cannabis (medicinal) - Spasticity and muscle spasm Important

Keywords :
spasticity in multiple sclerosis, spasticity in MS, THC, cannabidiol, CBD, Cancard, Payment by Responder, MS , Sativex oromucosal spray, cannabis-based products for medicinal use, CBPM
Brand Names Include :
Sativex
Important Information :
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Oromucosal spray
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Evidence Review
Sativex for spasticity in Multiple Sclerosis - Evidence Review - November 2021.pdf
Webpage
NHS England advice - Cannabis-based products for medicinal use
Information
Cancard information for GPs - Dec 2020
01 December 2023

Committee Recommendations

Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:

https://www.england.nhs.uk/medicines-2/support-for-prescribers/cannabis-based-products-for-medicinal-use/

02 March 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee agree that Sativex for the treatment of spasticity in Multiple Sclerosis patients should be given a BLUE (no information sheet) traffic light status. 

The specialist team will prescribe the first 12 weeks of treatment using the payment by responder scheme (3 vials free of charge), and will determine response to Sativex in line with the information in the licence [https://www.medicines.org.uk/emc/product/602], before transfer of care is requested.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.02.02. Skeletal muscle relaxants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More